+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pediatric Diabetes Therapeutic Market Size, Share and Trends Analysis Report by Type (Type 1, Type 2), Treatment (Insulin, GLP-1, Biguanide, SGLT2), Route of Administration, Distribution Channel, and Region 2024-2030

  • PDF Icon

    Report

  • 110 Pages
  • September 2024
  • Region: Global
  • Grand View Research
  • ID: 6009687
Description Jump to:
The global pediatric diabetes therapeutic market size is anticipated to reach USD 22.14 billion by 2030, growing at a CAGR of 13.9% from 2024 to 2030. The market is primarily driven by the rising prevalence of diabetes among children and the increasing focus on early diagnosis and effective management. The International Diabetes Federation (IDF) estimates that in 2022, out of the 8.75 million people living with type 1 diabetes (T1D) worldwide, only 1.52 million were under the age of 20. This surge is largely due to genetic predisposition, environmental factors, and changes in lifestyle patterns.

Technological advancements in diabetes management are anticipated to positively impact market growth. Innovations such as continuous glucose monitors (CGMs), insulin pumps, and artificial pancreas systems enable better glucose control, reducing the risk of complications. For example, in June 2023, the U.S. FDA approved Synjardy (a combination of metformin hydrochloride and empagliflozin) and Jardiance (empagliflozin) for use in children aged 10 and older with type 2 diabetic (T2D), as an adjunct to diet and exercise for better blood sugar control. This approval is expected to significantly enhance treatment options for pediatric with T2D, encouraging broader adoption of these medications in clinical practice. It marks a critical step in expanding access to effective therapies for younger patients, leading to improved disease management and better long-term health outcomes.

Furthermore, the growing awareness and early diagnosis of disease in children have led to an increase in the adoption of various treatment options, including insulin therapies, biguanides, GLP-1 receptor agonists, and SGLT2 inhibitors. The market is also driven by supportive government initiatives and policies aimed at improving access to diabetic care for children. As the global children population continues to rise, along with the increasing prevalence of diabetes, the demand for diabetic treatment is expected to grow significantly during the forecast period.

Pediatric Diabetes Therapeutic Market Report Highlights

  • The type 1 segment held the largest revenue share of 79.32% in 2023. This can be attributed to the increasing incidence and prevalence of type 1 disease and high demand for new therapy treatment across worldwide.
  • In treatment, the insulin segment is held the largest share of 35.88% of the market in 2023. This can be attributed to the development and commercialization of novel delivery systems to deliver insulin safely and effectively to children’s patients without harm.
  • In route of administration, the parenteral segment is held the largest share of 62.50% of the market in 2023. This can be attributed to the growing approval of new subcutaneous and intravenous medicine for treatment of pediatric diabetes patient.
  • In distribution channel, the retail pharmacies segment is held the largest share of 47.49% of the market in 2023. This can be attributed to its advantages such as easy accessibility and availability of medication to refill prescriptions of pediatric patients for diabetes treatment.
  • North America dominated the market in 2023 with a share of 41.49%, owing to factors such as advanced healthcare infrastructure, increasing prevalence of diabetic in children, and favorable regulatory and reimbursement for clinical trial and treatment.

The leading players in the Pediatric Diabetes Therapeutic market include:

  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • Sanofi
  • Vertex Pharmaceuticals Incorporated
  • Novo Nordisk A/S
  • AstraZeneca
  • MannKind Corporation
  • Xeris Pharmaceuticals
  • Amphastar Pharmaceuticals, Inc.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Treatment
1.2.3. Route of Administration
1.2.4. Distribution Channel
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product and treatment outlook
2.2.2. Route of administration and distribution channel outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Pediatric diabetes therapeutic market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising incidence of diabetic diseases in children
3.2.1.2. Rising awareness about diabetes
3.2.1.3. Advancement in treatment methodologies
3.2.2. Market restraint analysis
3.2.2.1. High cost of treatment
3.2.2.2. Stringent regulations pertaining to drug approval
3.3. Pediatric Diabetes Therapeutic Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pipeline Analysis
Chapter 4. Pediatric diabetes therapeutic market: Type Estimates & Trend Analysis
4.1. Global Pediatric Diabetes Therapeutic Market: Type Dashboard
4.2. Global Pediatric Diabetes Therapeutic Market: Type Movement Analysis
4.3. Global Pediatric Diabetes Therapeutic Market By Type, Revenue (USD Million)
4.4. Type 1
4.4.1. Type 1 market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Type 2
4.5.1. Type 2 market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Pediatric diabetes therapeutic market: Treatment Estimates & Trend Analysis
5.1. Global Pediatric Diabetes Therapeutic Market: Treatment Dashboard
5.2. Global Pediatric Diabetes Therapeutic Market: Treatment Movement Analysis
5.3. Global Pediatric Diabetes Therapeutic Market Estimates and Forecasts, By Treatment, Revenue (USD Million)
5.4. Insulin
5.4.1. Insulin market estimates and forecasts 2018 to 2030 (USD Million)
5.5. GLP-1 Receptor Agonists
5.5.1. GLP-1 Receptor Agonists market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Biguanide
5.6.1. Biguanide market estimates and forecasts 2018 to 2030 (USD Million)
5.7. SGLT2 Inhibitors
5.8. SGLT2 Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
5.9. Others
5.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Pediatric diabetes therapeutic market: Route of Administration Estimates & Trend Analysis
6.1. Global Pediatric Diabetes Therapeutic Market: Route of Administration Dashboard
6.2. Global Pediatric Diabetes Therapeutic Market: Route of Administration Movement Analysis
6.3. Global Pediatric Diabetes Therapeutic Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
6.4. Oral
6.4.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Parenteral
6.5.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Others
6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Pediatric diabetes therapeutic market: Distribution Channel Estimates & Trend Analysis
7.1. Global Pediatric Diabetes Therapeutic Market: Distribution Channel Dashboard
7.2. Global Pediatric Diabetes Therapeutic Market: Distribution Channel Movement Analysis
7.3. Global Pediatric Diabetes Therapeutic Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
7.4. Hospital Pharmacies
7.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Retail Pharmacies
7.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Online Pharmacies
7.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Pediatric diabetes therapeutic market: Regional Estimates & Trend Analysis By Product, Application, and End Use
8.1. Regional Dashboard
8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.3. North America
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework/ reimbursement structure
8.3.1.3. Competitive scenario
8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
8.3.2. Canada
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework/ reimbursement structure
8.3.2.3. Competitive scenario
8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
8.3.3. Mexico
8.3.3.1. Key country dynamics
8.3.3.2. Regulatory framework/ reimbursement structure
8.3.3.3. Competitive scenario
8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework/ reimbursement structure
8.4.1.3. Competitive scenario
8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
8.4.2. Germany
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework/ reimbursement structure
8.4.2.3. Competitive scenario
8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
8.4.3. France
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework/ reimbursement structure
8.4.3.3. Competitive scenario
8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
8.4.4. Italy
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework/ reimbursement structure
8.4.4.3. Competitive scenario
8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
8.4.5. Spain
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework/ reimbursement structure
8.4.5.3. Competitive scenario
8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
8.4.6. Norway
8.4.6.1. Key country dynamics
8.4.6.2. Regulatory framework/ reimbursement structure
8.4.6.3. Competitive scenario
8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
8.4.7. Sweden
8.4.7.1. Key country dynamics
8.4.7.2. Regulatory framework/ reimbursement structure
8.4.7.3. Competitive scenario
8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
8.4.8. Denmark
8.4.8.1. Key country dynamics
8.4.8.2. Regulatory framework/ reimbursement structure
8.4.8.3. Competitive scenario
8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
8.5.2. China
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
8.5.3. India
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
8.5.4. Australia
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework/ reimbursement structure
8.5.4.3. Competitive scenario
8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
8.5.5. South Korea
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework/ reimbursement structure
8.5.5.3. Competitive scenario
8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
8.5.6. Thailand
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework/ reimbursement structure
8.5.6.3. Competitive scenario
8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
8.6.2. Argentina
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
8.7.3. UAE
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
8.7.4. Kuwait
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
9.3.1. Key company market share analysis, 2023
9.3.2. Boehringer Ingelheim International GmbH.
9.3.2.1. Company overview
9.3.2.2. Financial performance
9.3.2.3. Product benchmarking
9.3.2.4. Strategic initiatives
9.3.3. Eli Lilly and Company
9.3.3.1. Company overview
9.3.3.2. Financial performance
9.3.3.3. Product benchmarking
9.3.3.4. Strategic initiatives
9.3.4. Sanofi
9.3.4.1. Company overview
9.3.4.2. Financial performance
9.3.4.3. Product benchmarking
9.3.4.4. Strategic initiatives
9.3.5. Vertex Pharmaceuticals Incorporated
9.3.5.1. Company overview
9.3.5.2. Financial performance
9.3.5.3. Product benchmarking
9.3.5.4. Strategic initiatives
9.3.6. Novo Nordisk A/S
9.3.6.1. Company overview
9.3.6.2. Financial performance
9.3.6.3. Product benchmarking
9.3.6.4. Strategic initiatives
9.3.7. AstraZeneca.
9.3.7.1. Company overview
9.3.7.2. Financial performance
9.3.7.3. Product benchmarking
9.3.7.4. Strategic initiatives
9.3.8. MannKind Corporation
9.3.8.1. Company overview
9.3.8.2. Financial performance
9.3.8.3. Product benchmarking
9.3.8.4. Strategic initiatives
9.3.9. Xeris Pharmaceuticals
9.3.9.1. Company overview
9.3.9.2. Financial performance
9.3.9.3. Product benchmarking
9.3.9.4. Strategic initiatives
9.3.10. Amphastar Pharmaceuticals, Inc.
9.3.10.1. Company overview
9.3.10.2. Financial performance
9.3.10.3. Product benchmarking
9.3.10.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America pediatric diabetes therapeutic market, by region, 2018 - 2030 (USD Million)
Table 3 North America pediatric diabetes therapeutic market, by Type, 2018 - 2030 (USD Million)
Table 4 North America pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 5 North America pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 6 North America pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 7 U.S. pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 8 U.S. pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 9 U.S. pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 10 U.S. pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 11 Canada pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 12 Canada pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 13 Canada pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 14 Canada pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 15 Mexico pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 16 Mexico pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 17 Mexico pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 18 Mexico pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 19 Europe pediatric diabetes therapeutic market, by region, 2018 - 2030 (USD Million)
Table 20 Europe pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 21 Europe pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 22 Europe pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 23 Europe pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 24 Germany pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 25 Germany pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 26 Germany pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 27 Germany pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 28 UK pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 29 UK pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 30 UK pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 31 UK pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 32 France pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 33 France pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 34 France pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 35 France pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 36 Italy pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 37 Italy pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 38 Italy pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 39 Italy pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 40 Spain pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 41 Spain pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 42 Spain pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 43 Spain pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 44 Denmark pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 45 Denmark pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 46 Denmark pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 47 Denmark pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 48 Sweden pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 49 Sweden pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 50 Sweden pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 51 Norway pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 52 Norway pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 53 Norway pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 54 Norway pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 55 Asia Pacific pediatric diabetes therapeutic market, by region, 2018 - 2030 (USD Million)
Table 56 Asia Pacific pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 57 Asia Pacific pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 58 Asia Pacific pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 59 Asia Pacific pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 60 China pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 61 China pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 62 China pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 63 China pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 64 Japan pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 65 Japan pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 66 Japan pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 67 Japan pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 68 India pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 69 India pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 70 India pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 71 India pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 72 South Korea pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 73 South Korea pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 74 South Korea pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 75 South Korea pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 76 Australia pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 77 Australia pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 78 Australia pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 79 Australia pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 80 Thailand pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 81 Thailand pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 82 Thailand pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 83 Thailand pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 84 Latin America pediatric diabetes therapeutic market, by region, 2018 - 2030 (USD Million)
Table 85 Latin America pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 86 Latin America pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 87 Latin America pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 88 Latin America pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 89 Brazil pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 90 Brazil pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 91 Brazil pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 92 Brazil pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 93 Argentina pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 94 Argentina pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 95 Argentina pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 96 Argentina pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 97 MEA pediatric diabetes therapeutic market, by region, 2018 - 2030 (USD Million)
Table 98 MEA pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 99 MEA pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 100 MEA pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 101 MEA pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 102 South Africa pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 103 South Africa pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 104 South Africa pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 105 South Africa pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 106 Saudi Arabia pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 107 Saudi Arabia pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 108 Saudi Arabia pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 109 Saudi Arabia pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 110 UAE pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 111 UAE pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 112 UAE pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 113 UAE pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
Table 114 Kuwait pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
Table 115 Kuwait pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
Table 116 Kuwait pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
Table 117 Kuwait pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Pediatric diabetes therapeutic market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Pediatric diabetes therapeutic market snapshot
Fig. 10 Pediatric diabetes therapeutic market driver impact
Fig. 11 Pediatric diabetes therapeutic market restraint impact
Fig. 12 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 13 Porter’s five forces analysis
Fig. 14 Value chain analysis
Fig. 15 Pediatric diabetes therapeutic market: Type Outlook and key takeaways
Fig. 16 Pediatric diabetes therapeutic market: Type movement analysis
Fig. 17 Type 1 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 Type 2 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Pediatric diabetes therapeutic market: Treatment outlook and key takeaways
Fig. 20 Pediatric diabetes therapeutic market: Treatment movement analysis
Fig. 21 Insulin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 GLP-1 Receptor Agonists market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Biguanide market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 SGLT2 Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Pediatric diabetes therapeutic market: Route of administration outlook and key takeaways
Fig. 27 Pediatric diabetes therapeutic market: Route of administration movement analysis
Fig. 28 Oral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Pediatric diabetes therapeutic market: Distribution channel outlook and key takeaways
Fig. 32 Pediatric diabetes therapeutic market: Distribution channel movement analysis
Fig. 33 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Global pediatric diabetes therapeutic market: Regional movement analysis
Fig. 37 Global pediatric diabetes therapeutic market: Regional outlook and key takeaways
Fig. 38 Global pediatric diabetes therapeutic market share and leading players
Fig. 39 North America, by country
Fig. 40 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 U.S. key country dynamics
Fig. 42 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Canada key country dynamics
Fig. 44 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Mexico key country dynamics
Fig. 46 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 UK key country dynamics
Fig. 49 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Germany key country dynamics
Fig. 51 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 France key country dynamics
Fig. 53 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Italy key country dynamics
Fig. 55 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Spain key country dynamics
Fig. 57 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Denmark key country dynamics
Fig. 59 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Sweden key country dynamics
Fig. 61 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Norway key country dynamics
Fig. 63 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 China key country dynamics
Fig. 66 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 Japan key country dynamics
Fig. 68 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 India key country dynamics
Fig. 70 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Thailand key country dynamics
Fig. 72 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 South Korea key country dynamics
Fig. 74 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 Australia key country dynamics
Fig. 76 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 78 Brazil key country dynamics
Fig. 79 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 Argentina key country dynamics
Fig. 81 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 82 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 South Africa key country dynamics
Fig. 84 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 85 Saudi Arabia key country dynamics
Fig. 86 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 87 UAE key country dynamics
Fig. 88 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 89 Kuwait key country dynamics
Fig. 90 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 Market share of key market players- pediatric diabetes therapeutic market

Companies Mentioned

The leading players in the Pediatric Diabetes Therapeutic market include:
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • Sanofi
  • Vertex Pharmaceuticals Incorporated
  • Novo Nordisk A/S
  • AstraZeneca
  • MannKind Corporation
  • Xeris Pharmaceuticals
  • Amphastar Pharmaceuticals, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages110
PublishedSeptember 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 8.92 Billion
Forecasted Market Value ( USD ) by 2030 $ 22.14 Billion
Compound Annual Growth Rate13.9%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Antidiabetics Market Size, Share & Trends Analysis Report by Drug Class (GLP-1 Receptor Agonists, Insulin), Type (Type 1, Type 2), Route of Administration (Oral, Intravenous), Distribution Channel, Region, and Segment Forecasts, 2024-2030 - Product Image

Antidiabetics Market Size, Share & Trends Analysis Report by Drug Class (GLP-1 Receptor Agonists, Insulin), Type (Type 1, Type 2), Route of Administration (Oral, Intravenous), Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • Report
  • 100 Pages
  • Global
From
Glucagon-Like Peptide 1 (GLP-1) Agonist market (2024 Edition): Analysis by Type, End-Use (Type 2 Diabetes, NASH, Obesity), By Distribution Channel, By Route of Administration, By Region, By Country: Market Insights and Forecast (2020-2030) - Product Image

Glucagon-Like Peptide 1 (GLP-1) Agonist market (2024 Edition): Analysis by Type, End-Use (Type 2 Diabetes, NASH, Obesity), By Distribution Channel, By Route of Administration, By Region, By Country: Market Insights and Forecast (2020-2030)

  • Report
  • 250 Pages
  • Global
From
GLP-1 Market: Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Active Compound Used, Type of GLP-1 Agonist Drugs, Type of Agonist, Route of Administration, Target indication, Geography, Leading Developers and Sales Forecast - Product Image

GLP-1 Market: Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Active Compound Used, Type of GLP-1 Agonist Drugs, Type of Agonist, Route of Administration, Target indication, Geography, Leading Developers and Sales Forecast

  • Report
  • Global
From
Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: Seven-Market Drug Forecast and Market Analysis - Product Image

Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: Seven-Market Drug Forecast and Market Analysis

  • Report
  • 93 Pages
  • Global
From
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast - Product Image

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast

  • Report
  • 16 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.